The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach (Q34777454)

4 August 2017

The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach (English)

1 reference

4 August 2017

9

1 reference

4 August 2017

E Losina

4

0 references

Milton Weinstein

5

object named as

M C Weinstein

1 reference

4 August 2017

13

K A Freedberg

1 reference

4 August 2017

1

Y Yazdanpanah

1 reference

4 August 2017

M Vray

2

1 reference

4 August 2017

J Meynard

3

1 reference

4 August 2017

L Morand-Joubert

6

1 reference

4 August 2017

S J Goldie

7

1 reference

4 August 2017

H E Hsu

8

1 reference

4 August 2017

C Dalban

10

1 reference

4 August 2017

P E Sax

11

1 reference

4 August 2017

P M Girard

12

1 reference

4 August 2017

1 October 2007

1 reference

4 August 2017

1 reference

4 August 2017

8

1 reference

4 August 2017

7

1 reference

4 August 2017

439-450

1 reference

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

4 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

7 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00491.X

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00491.X

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00491.X

Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00491.X

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00491.X

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00491.X

The cost effectiveness of combination antiretroviral therapy for HIV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00491.X

Deriving a preference-based single index from the UK SF-36 Health Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00491.X

The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00491.X

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00491.X

HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00491.X

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00491.X

Response to 'limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis'.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3073616

The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load

26 October 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00491.X

Effect of Highly Active Antiretroviral Therapy on Time to Acquired Immunodeficiency Syndrome or Death using Marginal Structural Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00491.X

Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17760736

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17760736

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17760736

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1468-1293.2007.00491.X

1 reference

4 August 2017

1 reference

4 August 2017

1 reference